Welcoming you for any type of article submission for the upcoming issue on/before February 26, 2021.


Review Article
Volume 6 Issue 7 - 2021
Current Understanding of Adipokines and Adipose Tissue: Roles and Functions
Jennifer J Brown1,2* and Vanessa Fiaud3
1Elizabeth City State University, Elizabeth City, North Carolina, United States
2Old Dominion University, Norfolk, Virginia, United States
3West Texas A and M University, Canyon, Texas, United States
*Corresponding Author: Jennifer J Brown, Elizabeth City State University, Elizabeth City, North Carolina, United States.
Received: July 23, 2021; Published: September 14, 2021




Abstract

Obesity rates and cardio metabolic diseases are on the rise in developing countries, giving cause for concern metabolic syndrome and type 2 diabetes are becoming more prevalent. Changes in the roles of adipose tissue paired with sharp increases in BMI have drawn attention to the secretory effects of adipocytes and adipokines on human physiology. This new realm of research targets revealing relationships between adipose tissue and its function as an endocrine organ and processes relating to inflammation, disease, and health. Research on adipose tissue storage locations, commonly studied adipokines and their affects, and novel peptides are presented. Nutrition, medication, and exercise as potential interventions are discussed.

Keywords: VAT; SAT; Beige (Brite) Adipose Tissue; Adipokines; Adiponectin; FGF21; IL-6; Leptin; Nesfatin; Resistin; Retinol Binding Protein- 4 (RBP4); TNF-α; Visfatin; Omentin; Apelin; Chemerin

References

  1. Adamczak M and A Wiecek. “The adipose tissue as an endocrine organ”. Seminars in Nephrology1 (2013): 2-13.
  2. Coelho M., et al. “Biochemistry of adipose tissue: an endocrine organ”. Archives of Medical Science2 (2013): 191-200.
  3. Haslam D. “Obesity: a medical history”. Obesity Reviews1 (2007): 31-36.
  4. Galic S., et al. “Adipose tissue as an endocrine organ”. Molecular and Cellular Endocrinology2 (2010): 129-139.
  5. General USPHSOotS., et al. “The Surgeon General's call to action to prevent and decrease overweight and obesity”. 2001: US Government Printing Office (2001).
  6. Benjamin RM. “The Surgeon General's vision for a healthy and fit nation”. Public Health Reports4 (2010): 514-515.
  7. Booth A., et al. “Detrimental and protective fat: body fat distribution and its relation to metabolic disease”. Hormone Molecular Biology and Clinical Investigation1 (2014): 13-27.
  8. Piya MK., et al. “Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin”. Journal of Endocrinology 1 (2013): T1-T15.
  9. Villarroya F. “Brown adipose tissue as an endocrine organ. in 20th European Congress of Endocrinology”. Bio Scientifica (2018).
  10. Sanchez-Gurmaches J and DA Guertin. “Adipocytes arise from multiple lineages that are heterogeneously and dynamically distributed”. Nature Communications 5 (2014): 4099.
  11. Villarroya J., et al. “An endocrine role for brown adipose tissue?” The American Journal of Physiology-Endocrinology and Metabolism 5 (2013): E567-572.
  12. Katsi V., et al. “Omentin, fat and heart: classical music with new instruments”. Heart, Lung and Circulation 9 (2014): 802-806.
  13. Booth A., et al. “Adipose tissue: an endocrine organ playing a role in metabolic regulation”. Hormone Molecular Biology and Clinical Investigation1 (2016): 25-42.
  14. Zyriax BC., et al. “The association of genetic markers for type 2 diabetes with prediabetic status - cross-sectional data of a diabetes prevention trial”. PLoS One 9 (2013): e75807.
  15. Stefan Camps., et al. Weight loss, weight maintenance, and adaptive thermogenesis”. American Journal of Clinical Nutrition5 (2013): 990-994.
  16. Harwood HJJr. “The adipocyte as an endocrine organ in the regulation of metabolic homeostasis”. Neuropharmacology 1 (2012): 57-75.
  17. Romacho T., et al. “Adipose tissue and its role in organ crosstalk”. Acta Physiologica 4 (2014): 733-753.
  18. Duval C., et al. “Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice”. Diabetes12 (2010): 3181-3191.
  19. Bays HE. “Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies”. The American Journal of Cardiology9 (2012): 4B-12B.
  20. Baltieri N., et al. “Protective role of perivascular adipose tissue in endothelial dysfunction and insulin-induced vasodilatation of hypercholesterolemic LDL receptor-deficient mice”. Frontiers in Physiology 9 (2018): 229.
  21. Chait A and LJ den Hartigh. “Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease”. Frontiers in Cardiovascular Medicine 7 (2020): 22.
  22. Zhang F., et al. “An adipose tissue atlas: an image-guided identification of human-like BAT and beige depots in rodents”. Cell Metabolism 1 (2018): 252-262.
  23. Kahn CR., et al. “Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome”. The Journal of Clinical Investigation 10 (2019): 3990-4000.
  24. Gunawardana SC and DW Piston. “Reversal of type 1 diabetes in mice by brown adipose tissue transplant”. Diabetes3 (2012): 674-682.
  25. Vosselman MJ., et al. “Energy dissipation in brown adipose tissue: from mice to men”. Molecular and Cellular Endocrinolog1-2 (2013): 43-50.
  26. Shao M., et al. “Zfp423 maintains white adipocyte identity through suppression of the beige cell thermogenic gene program”. Cell Metabolism6 (2016): 1167-1184.
  27. Scherer PE., et al. “A novel serum protein similar to C1q, produced exclusively in adipocytes”. Journal of Biological Chemistry45 (1995): 26746-267469.
  28. Zhang Y., et al. “Positional cloning of the mouse obese gene and its human homologue”. Nature6505 (1994): 425-432.
  29. Bays HE., et al. “Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association”. Journal of Clinical Lipidology4 (2013): 304-383.
  30. Hivert MF., et al. “Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance”. The Journal of Clinical Endocrinology and Metabolism8 (2008): 3165-3172.
  31. Kishida K., et al. “Relationships between circulating adiponectin levels and fat distribution in obese subjects”. Journal of Atherosclerosis and Thrombosis (2011): 1103020354-1103020354.
  32. Samaras K., et al. “Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes”. Obesity 5 (2010): 884-889.
  33. Fang H and R Judd. “Adiponectin regulation and function”. Comprehensive Physiology 8 (2018): 1031-1063.
  34. Bergmann K and G Sypniewska. “Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers?” Clinical Chemistry and Laboratory Medicine 1 (2013): 177-185.
  35. Coskun T., et al. “Fibroblast growth factor 21 corrects obesity in mice”. Endocrinology12 (2008): 6018-6027.
  36. Markan KR., et al. “Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding”. Diabetes12 (2014): 4057-4063.
  37. Lazar MA. “How obesity causes diabetes: Not a tall tale”. Science 307 (2005): 373-375.
  38. Fried SK., et al. “Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid”. The Journal of Clinical Endocrinology and Metabolism 83 (1998): 847-850.
  39. Senn JJ., et al. “Interleukin-6 induces cellular insulin resistance in hepatocytes”. Diabetes12 (2002): 3391-3399.
  40. Rotter V., et al. “Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects”. Journal of Biological Chemistry46 (2003): 45777-45784.
  41. Villarroya F., et al. “Brown adipose tissue as a secretory organ”. Nature Reviews Endocrinology1 (2017): 26.
  42. Farooqi IS and S O'Rahilly. “20 years of leptin: human disorders of leptin action”. Journal of Endocrinology1 (2014): T63-T70.
  43. Wauman J., et al. “The Leptin Receptor Complex: Heavier Than Expected?” Frontiers in Endocrinology 8 (2017): 30-30.
  44. Morioka T., et al. “Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes”. Cardiovascular Diabetology 1 (2014): 10.
  45. Deniz R., et al. “Nesfatin-1 and other hormone alterations in polycystic ovary syndrome”. Endocrine 3 (2012): 694-699.
  46. Li QC., et al. “Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans”. Regulatory Peptides 1-3 (2010): 72-77.
  47. Gunay H., et al. “Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder”. Psychoneuroendocrinology 12 (2012): 1949-1953.
  48. Mogharnasi M., et al. “Effects of upper-body resistance exercise training on serum nesfatin-1 level, insulin resistance, and body composition in obese paraplegic men”. Disability and Health Journal 1 (2019): 29-34.
  49. Golestani F., et al. “The effects of spirulina under high-intensity interval training on levels of nesfatin-1, omentin-1, and lipid profiles in overweight and obese females: A randomized, controlled, single-blind trial”. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences (2021): 26.
  50. Dore R., et al. “Nesfatin-1: functions and physiology of a novel regulatory peptide”. Journal of Endocrinology 1 (2017): R45-R65.
  51. Yuan JH., et al. “Nesfatin-1 in the lateral parabrachial nucleus inhibits food intake, modulates excitability of glucosensing neurons, and enhances UCP1 expression in brown adipose tissue”. Frontiers in Physiology 8 (2017): 235.
  52. Tekin T., et al. “Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome”. The Eurasian Journal of Medicine 3 (2019): 280-284.
  53. Zahorska-Markiewicz B. “Metabolic effects associated with adipose tissue distribution”. Advances in Medical Sciences 51 (2006): 111-114.
  54. Xu W., et al. “Detection of Prediabetes and Undiagnosed Type 2 Diabetes: A Large Population-Based Study”. Canadian Journal of Diabetes3 (2012): 108-113.
  55. López-Bermejo A., et al. “Serum visfatin increases with progressive β-cell deterioration”. Diabetes10 (2006): 2871-2875.
  56. Revollo JR., et al. “Nampt/PBEF/visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme”. Cell Metabolism5 (2007): 363-375.
  57. Shibata R., et al. “Omentin as a novel biomarker of metabolic risk factors”. Diabetology and Metabolic Syndrome1 (2012): 37.
  58. Zhong X., et al. “Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway”. Biochemical and Biophysical Research Communications2 (2012): 401-4006.
  59. Kazama K., et al. “Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells”. European Journal of Pharmacology1-3 (2012): 116-123.
  60. Moreno-Navarrete JM., et al. “Circulating omentin concentration increases after weight loss”. Nutrition and Metabolism1 (2010): 27.
  61. Attané C., et al. “Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice”. Diabetes2 (2012): 310-320.
  62. Castan-Laurell I., et al. “Apelin, a promising target for type 2 diabetes treatment?” Trends in Endocrinology and Metabolism5 (2012): 234-241.
  63. Catalán V., et al. “Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-α stimulates mRNA levels of chemerin in visceral adipocytes from obese patients”. Surgery for Obesity and Related Diseases2 (2013): 306-314.
  64. Hart R and DR Greaves. “Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5”. The Journal of Immunology6 (2010): 3728-3739.
  65. Lehrke M., et al. “Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis”. European Journal of Endocrinology2 (2009): 339-344.
  66. Ali TM and K Al Hadidi. “Chemerin is associated with markers of inflammation and predictors of atherosclerosis in Saudi subjects with metabolic syndrome and type 2 diabetes mellitus”. Beni-Suef University Journal of Basic and Applied Sciences2 (2013): 86-95.
  67. Rhee EJ. “Chemerin: A Novel Link between Inflammation and Atherosclerosis?” Diabetes and Metabolism Journal3 (2011): 216-218.
  68. Yu S., et al. “Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients”. Chinese Medical Journal 19 (2012): 3440-3444.
  69. Heggen E., et al. “Effect of a low-fat versus a low-gycemic-load diet on inflammatory biomarker and adipokine concentrations”. Metabolic Syndrome and Related Disorders 6 (2012): 437-442.
  70. Qi L., et al. “Adipocyte CREB promotes insulin resistance in obesity”. Cell Metabolism 3 (2009): 277-286.
  71. Hsia J., et al. “Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol< 50 mg/dl with rosuvastatin: the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)”. Journal of the American College of Cardiology16 (2011): 1666-1675.
  72. Oh S., et al. “Exercise reduces inflammation and oxidative stress in obesity-related liver diseases”. Medicine and Science in Sports and Exercise 12 (2013): 2214-2222.
  73. You T., et al. “Effects of exercise training on chronic inflammation in obesity: current evidence and potential mechanisms”. Sports Medicine4 (2013): 243-256.
  74. Kim JS., et al. “Effect of exercise training of different intensities on anti-inflammatory reaction in streptozotocin-induced diabetic rats”. Biology of Sport1 (2014): 73-79.
Citation: Jennifer J Brown and Vanessa Fiaud. “Current Understanding of Adipokines and Adipose Tissue: Roles and Functions”. EC Endocrinology and Metabolic Research 6.7 (2021): 01-12.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


September Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the September issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before September 28, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk